Santersus AG

Based in Switzerland, Santersus AG specializes in innovative therapeutic apheresis solutions, particularly the NucleoCapture device, aimed at addressing severe health challenges through selective blood purification. Santersus AG, founded in 2017, operates from Zurich, Switzerland, focusing on therapeutic apheresis. The company has executed one deal as of December 2025 and seeks to enhance its market presence. Santersus specializes in innovative therapeutic apheresis solutions, with a primary focus on the NucleoCapture selective apheresis device.

This first-in-class product is designed to remove neutrophil extracellular traps (NETs) from patient blood, addressing critical health challenges associated with conditions such as sepsis, COVID-19, cancer, acute organ failure, autoimmune diseases like lupus, and neurodegenerative disorders including Alzheimer’s disease. The device functions by selectively capturing and extracting these harmful cellular structures, thereby mitigating their detrimental effects on the immune system and inflammatory response. Santersus targets hospitals, clinics, and healthcare providers across Europe and North America, providing treatment options to patients suffering from severe inflammatory and immune-mediated conditions. By revolutionizing blood purification practices, Santersus aims to enhance patient outcomes and advance the standard of care in therapeutic apheresis.

The business model of Santersus revolves around the sale of its NucleoCapture device to healthcare institutions, establishing direct B2B transactions with hospitals and clinics. Revenue generation is primarily driven through the initial purchase of the device, along with potential ongoing maintenance and support agreements. These agreements may include service packages that ensure optimal device functionality and training for medical staff. Revenue is further augmented by partnerships with healthcare providers that may involve collaborative research and development efforts aimed at improving the efficacy of the device in various clinical settings.

Specific pricing plans or transaction costs associated with the NucleoCapture device and related services are structured to reflect the value provided to healthcare institutions managing complex patient cases. In December 2025, Santersus AG raised an undisclosed amount in Series A funding led by new investor Norcliffe Capital, with participation from Terumo Ventures. The company will use the funding to advance NucleoCapture into pivotal clinical trials for sepsis and systemic lupus erythematosus and accelerate pipeline programs in organ transplantation and neurodegeneration.